

# FORM 11

## NOTICE OF PROPOSED STOCK OPTION GRANT OR AMENDMENT

Name of Listed Issuer: **ORTHO REGENERATIVE TECHNOLOGIES INC.** (the "Issuer").

Trading Symbol: **ORTH**

Date: **June 19, 2019**

### 1. New Options Granted:

Date of Grant: June 19, 2019

Name of Optionee	Position (Director/ Officer/ Employee/ Consultant/ Management Company)	Insider Yes or No?	No. of Optioned Shares	Exercise Price	Expiry Date	No. of Options Granted in Past 12 Months
Claude LeDuc	Director and Officer	Yes	500,000	\$0.36	June 19, 2024	nil
Pierre Laurin	Director	Yes	100,000	\$0.36	June 19, 2024	nil
Nathalie Therrien	Consultant	No	100,000	\$0.36	June 19, 2024	nil
Frédéric Dumais	Consultant	No	50,000	\$0.36	June 19, 2024	nil

Total Number of optioned shares proposed for acceptance: **750,000**.

## 2. Other Presently Outstanding Options:

Name of Optionee	No. of Optioned Shares	Exercise Price	Original Date of Grant	Expiry Date
Dr. Scott Rodeo	60,000	\$0.10	July 31, 2015	July 31, 2020
Dr. Martyn Snow	100,000	\$0.10	July 31, 2015	July 31, 2020
Dr. Jack Farr	100,000	\$0.10	July 31, 2015	July 31, 2020
Guy Paul Allard	100,000	\$0.50	June 23, 2016	June 23, 2021
Dr. Brent Norton	350,000	\$0.50	May 17 2017	May 17, 2022
François-Xavier Lacasse	100,000	\$0.50	July 17, 2017	July 17, 2022
Tom E.S. Wright	100,000	\$0.50	September 26, 2017	September 26, 2022
Dr. Jacques Toueg	100,000	\$0.50	December 15, 2017	December 15, 2017
Hamsa Capital Inc.	100,000	\$0.50	June 19, 2018	December 19, 2019
9216-3815 Québec Inc.	100,000	\$0.50	June 19, 2018	December 19, 2019
Luc Mainville	465,000	\$0.50	September 17, 2018	September 17, 2023

(1) Set out number of optioned shares for each grant with different terms.

## 3. Additional Information

- (a) If shareholder approval was required for the grant of options (including prior approval of a stock option plan), state the date that the shareholder meeting approving the grant was or will be held. **N/A**
- (b) State the date of the news release announcing the grant of options. **N/A**
- (c) State the total issued and outstanding share capital at the date of grant or amendment. **24,752,424**
- (d) State, as a percentage of the issued and outstanding shares of the Issuer indicated in (c) above, the aggregate number of shares that are subject to incentive stock options, including new options, amended options and other presently outstanding options. **9.8%**

- (e) If the new options are being granted pursuant to a stock option plan, state the number of remaining shares reserved for issuance under the plan. **50,242**
- (f) If the Issuer has completed a public distribution of its securities within 90 days of the date of grant, state the per share price paid by the public investors. **N/A**
- (g) Describe the particulars of any proposed material changes in the affairs of the Issuer. **N/A**

#### **4. Certificate of Compliance**

The undersigned hereby certifies that:

- 1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
- 2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
- 3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
- 4. All of the information in this Form 11 Notice of Proposed Stock Option Grant or Amendment is true.

Dated June 19, 2019.

Guy Paul Allard  
Name of Director or Senior Officer

(s) Guy Paul Allard  
Signature

VP Legal and Corporate Secretary  
Official Capacity